ERBB2 and breast carcinoma: Although a low percentage of breast carcinomas express c-KIT, if any, 20-42% of triple-­negative breast cancers, which lack expression of estrogen receptor, progesterone receptor, and HER-2/neu and have a significantly higher probability of relapse and poorer overall survival when compared with other breast cancer types, do express it [110-112].